| Imfinzi (durvalumab) / AstraZeneca |
ACTRN12624000348550: A pilot study, defining the Immunophenotype of immunotherapy resistance with 89Zr- Durvalumab (MEDI4736) and CD8 T-cell PET/CT. |
|
|
| Not yet recruiting | N/A | 5 | | | Peter MacCallum Cancer Centre, Victorian Cancer Agency, Peter MacCallum Cancer Centre, AstraZeneca | Non-small cell lung cancer
| | | | |
| Unknown status | N/A | 20 | NA | Durvalumab, Durvalumab injection, Lenvatinib Oral Product, LENVIMA | Shanghai First Maternity and Infant Hospital | Endometrial Cancer | 05/21 | 05/21 | | |
NCT03643484: IMFINZI Specific-Clinical Experience Investigation in Patients With NSCLC After Definitive Chemoradiation Therapy |
|
|
| Completed | N/A | 634 | Japan | | AstraZeneca | Carcinoma, Non-Small-Cell Lung | 06/21 | 06/21 | | |
NCT02563925: Brain Irradiation and Tremelimumab in Metastatic Breast Cancer |
|
|
| Completed | N/A | 28 | US | Brain radiotherapy or Stereotactic Radiosurgery, Tremelimumab, HER2 directed therapy, Durvalumab | Memorial Sloan Kettering Cancer Center, MedImmune LLC | Metastatic Breast Cancer | 07/21 | 07/21 | | |
NCT02492867: A Pilot Study of Response-Driven Adaptive Radiation Therapy for Patients With Locally Advanced Non-Small Cell Lung Cancer |
|
|
| Completed | N/A | 49 | US | Response-driven Adaptive Radiation Therapy, Carboplatin, Paclitaxel, FDG-PET, Positron Emission Tomography Scan, V/Q SPECT, Single-photon Emission Computed Tomography Scan, Durvalumab | University of Michigan Rogel Cancer Center | Carcinoma, Non-Small-Cell Lung | 11/21 | 04/22 | | |
S-REAL, NCT04285866: Spanish Real World Data on Patients Treated With Durvalumab After Chemoradiotherapy. |
|
|
| Completed | N/A | 245 | Europe | Durvalumab, MEDI4736 | Fundación GECP | Small Cell Lung Cancer (SCLC) | 12/21 | 12/21 | | |
Dulect2020-1, NCT04443322: Durvalumab and Lenvatinib in Participants With Locally Advanced and Metastatic Hepatocellular Carcinoma ( ) |
|
|
| Recruiting | N/A | 20 | RoW | Durvalumab Injection, Durvalumab, Imfinzi, Lenvatinib 4 MG, Lenvima | RenJi Hospital | Liver Carcinoma, Liver Transplant; Complications | 12/21 | 12/25 | | |
ChiCTR2100043656: Clinical study of Xiaoyan granule combined with Durvalumab in the treatment of advanced NSCLC |
|
|
| Recruiting | N/A | 50 | China | Xiaoyan Decoction+Durvalumab ;Durvalumab | The First Teaching Hospital of Tianjin University of TCM ; The First Teaching Hospital of Tianjin University of TCM, self-raised | lung cancer | | | | |
Lung-MAP, NCT02154490: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer |
|
|
| Completed | N/A | 1864 | Canada, US | Docetaxel, Docecad, RP56976, Taxotere, Taxotere Injection Concentrate, Durvalumab, Imfinzi, Immunoglobulin G1, Anti-(Human Protein B7-H1) (Human Monoclonal MEDI4736 Heavy Chain), Disulfide with Human Monoclonal MEDI4736 Kappa-chain, Dimer, MEDI-4736, MEDI4736, Erlotinib Hydrochloride, Cp-358,774, OSI-774, Tarceva, FGFR Inhibitor AZD4547, AZD4547, Ipilimumab, Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, BMS-734016, MDX-010, MDX-CTLA4, Yervoy, Laboratory Biomarker Analysis, Nivolumab, BMS-936558, MDX-1106, NIVO, ONO-4538, Opdivo, Palbociclib, Ibrance, PD-0332991, PD-332991, Pharmacological Study, Rilotumumab, AMG 102, Anti-HGF Monoclonal Antibody AMG 102, Fully Human Anti-HGF Monoclonal Antibody AMG 102, Talazoparib, BMN 673, BMN-673, Taselisib, GDC-0032, Tremelimumab, Anti-CTLA4 Human Monoclonal Antibody CP-675,206, CP-675, CP-675,206, CP-675206, ticilimumab | SWOG Cancer Research Network, National Cancer Institute (NCI) | Recurrent Squamous Cell Lung Carcinoma, Stage IV Squamous Cell Lung Carcinoma AJCC v7 | 04/22 | 04/22 | | |
|
|
|
|
| Completed | N/A | 662 | Canada | Durvalumab, Imfinzi | AstraZeneca | Non-small Cell Lung Cancer | 08/22 | 08/22 | | |
CODAK, NCT04667312: Observational Study of Durvalumab in Patients With Non-small-cell Lung Cancer in the United Kingdom |
|
|
| Completed | N/A | 115 | Europe | Durvalumab, Imfinzi | AstraZeneca | Non-Small Cell Lung Cancer NSCLC | 09/22 | 09/22 | | |
ChiCTR2000039730: A prospective, multi-center, single-arm, open phase Ib clinical study of safety, tolerability and preliminary efficacy of anlotinib combined with duvalizumab in patients with advanced gastric or colorectal cancer who have failed second-line treatment |
|
|
| Recruiting | N/A | 50 | | Anlotinib combined with Duvalizumab | The Affiliated Hospital of Qingdao University; The Affiliated Hospital of Qingdao University, Self financing | Advanced colorectal cancer or stomach cancer | | | | |
| Approved for marketing | N/A | | US | Durvalumab, Imfinzi, Tremelimumab | AstraZeneca | Unresectable Hepatocellular Carcinoma | | | | |
EAP DURVA LUNG, NCT04948411: Durvalumab as Maintenance in Patients Who Received Chemoradiotherapy for Unresectable Stage III NSCLC: Real World Data From an Expanded Access Program in Brazil |
|
|
| Completed | N/A | 33 | RoW | | Latin American Cooperative Oncology Group | Carcinoma, Non-Small-Cell Lung | 02/23 | 02/23 | | |
iDETECT, NCT04884269: A Non Interventional Pilot Study on Machine Learning for ILD Detection Based on the Patient Data From Digital Devices in Unresectable Stage III Non-Small Cell Lung Cancer Patients Receiving Durvalumab |
|
|
| Completed | N/A | 144 | Japan | | AstraZeneca | Carcinoma, Non-Small-Cell Lung | 03/23 | 03/23 | | |
DRIVE, NCT05761977: Durvalumab in Combination With Standard Chemotherapy of Patients With Extensive Stage Small Cell Lung Cancer |
|
|
| Recruiting | N/A | 50 | Europe | | Hellenic Cooperative Oncology Group | Small-cell Lung Cancer, Extensive-stage Small-cell Lung Cancer | 04/23 | 04/24 | | |
| Recruiting | N/A | 126 | Europe | | Leiden University Medical Center, The Netherlands Cancer Institute, Jessa Hospital | Non Small Cell Lung Cancer Stage III, Immunotherapy | 04/23 | 07/23 | | |
PACIFIC AA, NCT04529564: Real-world Data on Stage III NSCLC Patients Treated With Durvalumab After Chemoradiotherapy in Asia Area |
|
|
| Completed | N/A | 106 | RoW | | AstraZeneca | Carcinoma, Non-Small-Cell Lung | 06/23 | 06/23 | | |
ChiCTR2000035210: Clinical study on the adjuvant treatment of postoperative cholangjocinoma with duvalizumab combined with GEMOX (gemcitabine+oxaliplatin) |
|
|
| Recruiting | N/A | 40 | | duvalizumab combined with GEMOX (gemcitabine+oxaliplatin) | Chinese PLA General Hospital (the 301st Hospital); Chinese PLA General Hospital (the 301st Hospital), self-funding | cholangiocarcinoma | | | | |
NCT04854590: IMFINZI Study in Patients With Extensive Stage Small Cell Lung Cancer |
|
|
| Completed | N/A | 248 | Japan | | AstraZeneca | Carcinoma, Small Cell | 08/23 | 08/23 | | |
Microdurva, NCT04680377: Using Microbiome to Predict Durvalumab Toxicity in Post- Concurrent Chemoradiation Therapy (CCRT) NSCLC Patients |
|
|
| Recruiting | N/A | 44 | US | | Jun Zhang, MD, PhD, Rhode Island Hospital | NSCLC, Stage III, Locally Advanced Lung Carcinoma | 12/25 | 12/26 | | |
NCT04364776: Radiomic Signature as Predictive Marker of Response to Chemoradiation and Durvalumab in Stage III NSCLC. |
|
|
| Active, not recruiting | N/A | 100 | Europe | Durvalumab | IRCCS Policlinico S. Matteo | Lung Cancer, Lung Cancer Stage III | 12/23 | 12/24 | | |
PACIFIC-R, NCT03798535: First Real-world Data on Unresectable Stage III NSCLC Patients Treated With Durvalumab After Chemoradiotherapy |
|
|
| Active, not recruiting | N/A | 1156 | Europe, RoW | | AstraZeneca | NSCLC | 06/24 | 06/24 | | |
|
| Recruiting | N/A | 4490 | Europe, US | Durvalumab-based combination therapies in observational study setting, Imfinzi | AstraZeneca, ICON plc | Hepatobiliary Cancers | 12/29 | 12/29 | | |
AYAME, NCT03995875: Real World Evidence of Long-term Safety and Efficacy in Patients Treated With Durvalumab After Concurrent Chemoradiation for Unresectable Stage III NSCLC |
|
|
| Completed | N/A | 529 | Japan | | AstraZeneca, Japan Lung Cancer Society | Carcinoma, Non-Small-Cell Lung | 01/24 | 01/24 | | |
| Recruiting | N/A | 42 | US | Radiation Therapy, radiotherapy, RT, Cetuximab, Erbitux, Chemotherapy, Cisplatin, Immunotherapy, pembrolizumab, Keytruda, nivolumab, Opdivo, durvalumab, Imfinzi | Loren Mell, MD | Head and Neck Cancer, Dysphagia, Oropharyngeal Dysphagia, Oropharynx Cancer, Oropharynx Squamous Cell Carcinoma | 12/23 | 12/24 | | |
ChiCTR2000037649: Hypofractionated Stereotactic Radiotherapy With PD-L1 Inhibitor and Bevacizumab in Patients With Recurrent High-Grade Gliomas: a Prospective Single Center Exploratory Clinical Trial |
|
|
| Not yet recruiting | N/A | 32 | China | Hypofractionated Stereotactic Radiotherapy + Durvalumab+ Bevacizumab | Huashan Hospital, Fudan University ; Huashan Hospital, Fudan University, Huashan Hospital, Fudan University | High-Grade Glioma | | | | |
NCT04807127: A Single-cell Approach to Identify Biomarkers of Pulmonary Toxicity for Immune Checkpoint Blockade |
|
|
| Recruiting | N/A | 60 | Europe | Immune checkpoint blockade, Pembrolizumab, Durvalumab, Targeted therapy, TKI, Radiotherapy | Universitaire Ziekenhuizen KU Leuven, KU Leuven | Pneumonitis, Interstitial, Immunotherapy, Immune-related Adverse Events | 01/25 | 01/25 | | |
PRECISION, NCT05027165: Prospective Evaluation of Immunological, Molecular-genetic, Image-based and Microbial Analyzes to Characterize Tumor Response and Control in Patients With Inoperable Stage III NSCLC Treated With Chemoradiotherapy Followed by Consolidation Therapy With Durvalumab |
|
|
| Active, not recruiting | N/A | 40 | Europe | Non-interventional | LMU Klinikum, Department of Internal Medicine V, Thoracic Oncology Centre Munich, LMU Munich, Munich, Germany, Institute of Pathology, Faculty of Medicine, LMU Munich, Munich, Germany, Asklepios Lung Clinic, Munich-Gauting, Germany, Department of Radiology, University Hospital, LMU Munich, Munich, Germany, Department of Nuclear Medicine, University Hospital, LMU Munich, Munich, Germany, Institute for Medical Information Processing, Biometry and Epidemiology, LMU München, Munich, Germany, Department of Medicine II, University Hospital, LMU Munich, Munich, Germany, Immunoanalytics Research Group Tissue Control of Immunocytes, Helmholtz Center Munich, Munich, Germany | Oncology, Biomarker, NSCLC, Stage III, Durvalumab, Chemoradiotherapy | 01/24 | 01/25 | | |
NCT04985851: To Evaluate the Efficacy of Durvalumab + Anlotinib in Terms of OS and PFS. |
|
|
| Active, not recruiting | N/A | 90 | RoW | durvalumab + anlotinib, Durvalumab | Shanghai Chest Hospital | Extensive-Stage Small-Cell Lung Cancer | 06/24 | 12/24 | | |
| Recruiting | N/A | 1800 | Europe | Nivolumab, Opdivo, Pembrolizumab, Keytruda, Ipilimumab, Yervoy, Durvalumab, Imfinzi, Tremelimumab, CP-675,206, Atezolizumab, Tecentriq, Bevacizumab, Avastin | CCTU- Cancer Theme, Microbiotica Ltd | Melanoma, Renal Cancer, Lung Cancer | 07/24 | 07/25 | | |
NCT04068168: Open Label, Multicenter, Real World Practice of Durvalumab in Lung Cancer (Imfinzi PMS) |
|
|
| Recruiting | N/A | 1500 | RoW | | AstraZeneca | Lung Cancer | 02/25 | 02/25 | | |
NCT05667064: Imfinzi/Imjudo uHCC Japan PMS _ Japan Post-Marketing Surveillance (PMS) Study |
|
|
| Recruiting | N/A | 300 | Japan | | AstraZeneca | Unresectable Hepatocellular Carcinoma | 12/26 | 12/26 | | |
TAD, NCT04517227: The Combination Therapy of TACE and Ablation With Durvalumab in Hepatocellular Carcinoma at Intermediate Stage |
|
|
| Not yet recruiting | N/A | 30 | NA | Durvalumab, IMFINZI, Transcatheter Hepatic Arterial Chemoembolization (TACE), Ablation | Fudan University | Hepatocellular Carcinoma | 06/25 | 10/25 | | |
NCT05826366: Imfinzi/Imjudo NSCLC Japan PMS_Japan Post-Marketing Surveillance (PMS) Study - CEI/SCEI |
|
|
| Active, not recruiting | N/A | 296 | Japan | | AstraZeneca | Carcinoma, Non-Small-Cell Lung | 11/25 | 11/25 | | |
NCT05835778: Imfinzi BTC Japan PMS_Japan Post-Marketing Surveillance (PMS) Study - CEI/SCEI |
|
|
| Recruiting | N/A | 200 | Japan | | AstraZeneca | Biliary Tract Cancer | 07/26 | 07/26 | | |
NCT05834413: Clinical Study on the Prevention of Driver Gene Negative II-IIIa Lung Cancer Recurrence and Metastasis by Staged Chinese Herbal Medicine Combined With Chemotherapy and Immune Checkpoint Inhibitors |
|
|
| Not yet recruiting | N/A | 367 | RoW | chemotherapy plus TCM 1&ICIs plusTCM2 placebo, chemotherapy plus TCM 1placebo &ICIs plus TCM2 placebo | Shanghai University of Traditional Chinese Medicine, Shanghai Pulmonary Hospital, Shanghai, China, Shanghai Chest Hospital, Fudan University, Shanghai Zhongshan Hospital, Ruijin Hospital | Lung Cancer | 06/26 | 06/26 | | |
EDUR-BRA, NCT06008353: A Real-World Assessment of the Demographic, Clinical Characteristics and Outcomes of a Brazilian Cohort of Previously Untreated Extensive Stage-Small Cell Lung Cancer Receiving Durvalumab Combined With Platinum-Etoposide in (ES-SCLC) in Brazil |
|
|
| Not yet recruiting | N/A | 60 | RoW | Observational study | Latin American Cooperative Oncology Group, AstraZeneca | Extensive-stage Small-cell Lung Cancer | 09/26 | 09/26 | | |
REFINE-IO, NCT06117891: An Observational Study to Learn More About How Well a Treatment Works When Given After Treatment With Atezolizumab and Bevacizumab or Another Similar Combination of Drugs in Adults With Liver Cancer That Cannot be Treated With Surgery |
|
|
| Recruiting | N/A | 300 | Europe, US, RoW | Atezolizumab, Bevacizumab, Durvalumab, Tremelimumab, | Bayer | Unresectable Hepatocellular Carcinoma | 11/26 | 02/27 | | |
NIS durvalumab, NCT05456867: A Multi-center, Non-interventional, Prospective Study of Durvalumab in Unresectable Locally Advanced NSCLC in Routine Clinical Practice in Russia |
|
|
| Recruiting | N/A | 250 | RoW | | AstraZeneca | NSCLC, Non-small-cell Lung Carcinoma | 11/26 | 11/26 | | |
ARSENAL, NCT05683977: A French Real-life Study: EvaluatioN of durvALumab Utilization and Effectiveness for First Line Extensive Stage Small Cell Lung Cancer. |
|
|
| Active, not recruiting | N/A | 254 | Europe | durvalumab | AstraZeneca, Kappa Santé | Small Cell Lung Carcinoma | 03/27 | 03/27 | | |
